Myriad suffers setback in attempt to block Ambry BRCA test

12-03-2014

Myriad suffers setback in attempt to block Ambry BRCA test

Photo: Repina Valeriya / Shutterstock.com

Genetic diagnostic company Myriad Genetics and other patent holders have been denied a motion for a preliminary injunction that would have kept rival company Ambry Genetics from selling its own test for the BRCA gene mutations that put women at risk of developing breast and ovarian cancer.


Myriad, Ambry, BRCA, US District Court for the District of Utah, genetic testing, preliminary injunction, cancer

LSIPR